Functional evidence for an active role of B-type natriuretic peptide in cardiac remodelling and pro-arrhythmogenicity

Cardiovascular Research

Volumn 95, Issue 1, 2012, Pages 59-68

  Thireau, Jérôme ^a   Karam, Sarah ^a   Fauconnier, Jérémy ^a   Roberge, Stéphanie ^a   Cassan, Cécile ^a   Cazorla, Olivier ^a   Aimond, Franck ^a   Lacampagne, Alain ^a   Babuty, Dominique ^b   Richard, Sylvain ^a  

^a UNIVERSITY OF MONTPELLIER   (France)

^b SERVICE DE DERMATOLOGIE   (France)

Author keywords

Arrhythmia; Calcium; Heart failure; Natriuretic peptide; Remodelling

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CALCIUM BINDING PROTEIN; METOPROLOL; RYANODINE RECEPTOR; S100A1 PROTEIN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARRHYTHMOGENESIS; ARTICLE; CALCIUM TRANSPORT; CONTROLLED STUDY; DIASTOLE; ELECTROCARDIOGRAPHY; HEART DISEASE; HEART RATE VARIABILITY; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE PRESSURE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; LEFT VENTRICLE REMODELLING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ANIMALS; ARRHYTHMIAS, CARDIAC; CALCIUM; ELECTROCARDIOGRAPHY; HEART FAILURE; MALE; METOPROLOL; MICE; MICE, INBRED C57BL; NATRIURETIC PEPTIDE, BRAIN; RECEPTORS, ADRENERGIC, BETA-1; S100 PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SYMPATHETIC NERVOUS SYSTEM; VAGUS NERVE; VENTRICULAR REMODELING;

EID: 84862869472     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs167     Document Type: Article

References (56)

1. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
2. Simon T, Becker R, Voss F, Bikou O, Hauck M, Licka M et al. Elevated B-type natriuretic peptide levels in patients with nonischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol 2008;97:306-309.
3. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350: 655-663.
4. Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N et al. Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail 2011; 13:460-465.
5. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
6. Topol EJ. Nesiritide-not verified. N Engl J Med 2005;353:113-116.
7. Aronson D, Burger AJ. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure. Am Heart J 2004;148:e16.
8. La Villa G, Bisi G, Lazzeri C, Fronzaroli C, Stefani L, Barletta G et al. Cardiovascular effects of brain natriuretic peptide in essential hypertension. Hypertension 1995;25: 1053-1057.
9. Cheng H, Lederer WJ. Calcium sparks. Physiol Rev 2008;88:1491-1545.
10. Fauconnier J, Thireau J, Reiken S, Cassan C, Richard S, Matecki S et al. Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci USA 2010;107:1559-1564.
11. Sipido KR, Volders PG, Vos MA, Verdonck F. Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy? Cardiovasc Res 2002;53:782-805.
12. Ikeda Y, Hoshijima M, Chien KR. Toward biologically targeted therapy of calcium cycling defects in heart failure. Physiology (Bethesda) 2008;23:6-16.
13. Toischer K, Kogler H, Tenderich G, Grebe C, Seidler T, Van PN et al. Elevated afterload, neuroendocrine stimulation, and human heart failure increase BNP levels and inhibit preload-dependent SERCA upregulation. Circ Heart Fail 2008;1:265-271.
14. Kogler H, Schott P, Toischer K, Milting H, Van PN, Kohlhaas M et al. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation 2006;113:2724-2732.
15. Chan NY, Seyedi N, Takano K, Levi R. An unsuspected property of natriuretic peptides: promotion of calcium-dependent catecholamine release via protein kinase gmediated phosphodiesterase type 3 inhibition. Circulation 2012;125:298-307.
16. Maczewski M, Mackiewicz U. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart. Cardiovasc Res 2008; 79:42-51.
17. Sun YL, Hu SJ, Wang LH, Hu Y, Zhou JY. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest 2005;128: 1812-1821.
18. Ahmet I, Morrell C, Lakatta EG, Talan MI. Therapeutic efficacy of a combination of a beta1-adrenoreceptor (AR) blocker and beta2-AR agonist in a rat model of postmyocardial infarction dilated heart failure exceeds that of a beta1-AR blocker plus angiotensin-converting enzyme inhibitor. J Pharmacol Exp Ther 2009;331:178-185.
19. Xydas S, Kherani AR, Chang JS, Klotz S, Hay I, Mutrie CJ et al. beta(2)-Adrenergic stimulation attenuates left ventricular remodeling, decreases apoptosis, and improves calcium homeostasis in a rodent model of ischemic cardiomyopathy. J Pharmacol Exp Ther 2006;317:553-561.
20. Harding VB, Jones LR, Lefkowitz RJ, Koch WJ, Rockman HA. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. Proc Natl Acad Sci USA 2001;98:5809-5814.
21. Thireau J, Aimond F, Poisson D, Zhang B, Bruneval P, Eder V et al. New insights into sexual dimorphism during progression of heart failure and rhythm disorders. Endocrinology 2010;151:1837-1845.
22. Das MK, Maskoun W, Shen C, Michael MA, Suradi H, Desai M et al. Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. Heart Rhythm 2010;7:74-80.
23. Thireau J, Zhang BL, Poisson D, Babuty D. Heart rate variability in mice: a theoretical and practical guide. Exp Physiol 2008;93:83-94.
24. Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Circulation 1996;93:1043-1065.
25. Thireau J, Poisson D, Zhang BL, Gillet L, Le Pecheur M, Andres C et al. Increased heart rate variability in mice overexpressing the Cu/Zn superoxide dismutase. Free Radic Biol Med 2008;45:396-403.
26. Cooley RL, Montano N, Cogliati C, van de Borne P, Richenbacher W, Oren R et al. Evidence for a central origin of the low-frequency oscillation in RR-interval variability. Circulation 1998;98:556-561.
27. van de Borne P, Montano N, Pagani M, Oren R, Somers VK. Absence of lowfrequency variability of sympathetic nerve activity in severe heart failure. Circulation 1997;95:1449-1454.
28. Wei S, Chow LT, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000;36:276-281.
29. Metoprolol in acute myocardial infarction. Other clinical findings and tolerability. The MIAMI Trial Research Group. Am J Cardiol 1985;56:39G-46G.
30. Most P, Pleger ST, Volkers M, Heidt B, Boerries M, Weichenhan D et al. Cardiac adenoviral S100A1 gene delivery rescues failing myocardium. J Clin Invest 2004;114: 1550-1563.
31. Shannon TR, Lew WY. Diastolic release of calcium from the sarcoplasmic reticulum: a potential target for treating triggered arrhythmias and heart failure. J Am Coll Cardiol 2009;53:2006-2008.
32. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M, Borries M et al. S100A1: a regulator of myocardial contractility. Proc Natl Acad Sci USA 2001;98:13889-13894.
33. Remppis A, Most P, Loffler E, Ehlermann P, Bernotat J, Pleger S et al. The small EF-hand Ca2+ binding protein S100A1 increases contractility and Ca2+ cycling in rat cardiac myocytes. Basic Res Cardiol 2002;97(Suppl. 1):I56-I62.
34. Kettlewell S, Most P, Currie S, Koch WJ, Smith GL. S100A1 increases the gain of excitation-contraction coupling in isolated rabbit ventricular cardiomyocytes. J Mol Cell Cardiol 2005;39:900-910.
35. Most P, Remppis A, Pleger ST, Katus HA, Koch WJ. S100A1: a novel inotropic regulator of cardiac performance. Transition from molecular physiology to pathophysiological relevance. Am J Physiol Regul Integr Comp Physiol 2007;293:R568-R577.
36. Rohde D, Ritterhoff J, Voelkers M, Katus HA, Parker TG, Most P. S100A1: a multifaceted therapeutic target in cardiovascular disease. J Cardiovasc Transl Res 2010; 3:525-537.
37. Reiken S, Gaburjakova M, Guatimosim S, Gomez AM, D'Armiento J, Burkhoff D et al. Protein kinase A phosphorylation of the cardiac calcium release channel (ryanodine receptor) in normal and failing hearts. Role of phosphatases and response to isoproterenol. J Biol Chem 2003;278:444-453.
38. Moilanen AM, Rysa J, Mustonen E, Serpi R, Aro J, Tokola H et al. Intramyocardial BNP gene delivery improves cardiac function through distinct context-dependent mechanisms. Circ Heart Fail 2011;4:483-495.
39. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol 2001;37: 1221-1227.
40. Fauchier L, Babuty D, Cosnay P, Autret ML, Fauchier JP. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. J Am Coll Cardiol 1997;30:1009-1014.
41. Dickey DM, Flora DR, Bryan PM, Xu X, Chen Y, Potter LR. Differential regulation of membrane guanylyl cyclases in congestive heart failure: natriuretic peptide receptor (NPR)-B, Not NPR-A, is the predominant natriuretic peptide receptor in the failing heart. Endocrinology 2007;148:3518-3522.
42. Qvigstad E, Moltzau LR, Aronsen JM, Nguyen CH, Hougen K, Sjaastad I et al. Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 2010;85:763-772.
43. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic betaadrenergic stimulation. Circulation 2004;109:1154-1160.
44. Kubo H, Margulies KB, Piacentino V 3rd, Gaughan JP, Houser SR. Patients with endstage congestive heart failure treated with beta-adrenergic receptor antagonists have improved ventricular myocyte calcium regulatory protein abundance. Circulation 2001; 104:1012-1018.
45. Reiken S, Wehrens XH, Vest JA, Barbone A, Klotz S, Mancini D et al. Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure. Circulation 2003;107:2459-2466.
46. Pleger ST, Most P, Boucher M, Soltys S, Chuprun JK, Pleger W et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 2007;115:2506-2515.
47. Volkers M, Loughrey CM, Macquaide N, Remppis A, DeGeorge BR Jr, Wegner FV et al. S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes. Cell Calcium 2007;41:135-143.
48. de Boer RA, Henning RH, Suurmeijer AJ, Pinto YM, Olthof E, Kirkels JH et al. Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. Int J Cardiol 2001;78:5-12.
49. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing human ventricles. Correlation with expression of the Ca(2+)-ATPase gene. Circ Res 1992;71:9-17.
50. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev Mol Cell Biol 2003;4:566-577.
51. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
52. Cohen-Solal A, Logeart D, Huang B, Cai D, Nieminen MS, Mebazaa A. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure. J Am Coll Cardiol 2009;53:2343-2348.
53. Fujimura M, Akaike M, Iwase T, Yoshida S, Sumitomo Y, Yagi S et al. Decrease in plasma brain natriuretic peptide level in the early phase after the start of carvedilol therapy is a novel predictor of long-term outcome in patients with chronic heart failure. Acta Cardiol 2009;64:589-595.
54. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-e479.
55. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
56. Byrne MJ, Power JM, Preovolos A, Mariani JA, Hajjar RJ, Kaye DM. Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther 2008;15:1550-1557.